Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

    NEXT STORY
    Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
    PREV STORY
    BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    The American Health Council Names Paul Aoun, DO/PhD, to Board of Physicians

    NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- With eight years in Endocrine and ...

    author_avatar
    NASDAQ Market News

    Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs

    author_avatar
    NASDAQ Market News

    The global soy protein ingredients market was valued at USD 8,144.29 million in 2020 and is projected to grow at a CAGR of 2.61% during the forecast period (2021 – 2026)

    author_avatar
    NASDAQ Market News